Table 1.

Summary of results from randomized trials comparing CD19-CAR T versus autologous stem cell transplant in patients with DLBCL who were refractory to R-CHOP or experienced disease progression within one year after the end of R-CHOP.

Study name and reference	ZUMA-7 (19)	TRANSFORM (21)	BELINDA (20)
CD19-CAR T-cell in experimental arm	Axi-cel	Liso-cel	Tisa-cel
Number of patients	359	184	322
Patients proceeding to CAR T vs. ASCT (%)	94% / 36%	97% / 47%	96% / 32%
Median time from registration to CAR T infusion	29 days	34 days	52 days
Bridging therapy allowed (% receiving bridging therapy)	Steroids only	One cycle of salvage chemotherapy (63%)	One cycle or more of salvage chemotherapy (97%, including 54% >1 regimen)
Crossover to CAR (% who proceeded)	Not planned (56% received cellular immunotherapy)	Planned per protocol (63%)	Planned per protocol (51%)
Median follow-up	25 months	17.5 months	10 months
Complete response rate (%)	65% vs 32%	74% vs 43%	28% vs 28%
Median event-free survival (months)	8.3 vs. 2	Not reached vs. 2.4	3 vs 3
Median progression-free survival (months)	14.7 vs. 3.7	Not reached vs. 6.2	na
Median overall survival (months)	Not reached vs. 35.1 (0.73)	Not reached vs. 29.9 (0.72)	16.9 vs. 15.3
Any grade CRS/NE (%)	92%/60%	49%/11%	61%/10%
Grade >=3 CRS/NE (%)	6%/21%	1%/4%	5%/2%

ASCT, high-dose therapy and autologous stem cell support; CAR T, chimeric antigen receptor T-cell therapy; RCHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; CRS, cytokine release syndrome; NE, neurologic event.